Effect of Nifedipine on Severe Experimental Cataract in Diabetic Rats

• Kametaka Sokichi

  Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, Japan

• Kasahara Takafumi

  Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, Japan

• Ueo Mayumi

  Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, Japan

• Takenaka Mariko

  Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, Japan

• Saito Maki

  Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, Japan

• Sakamoto Kenji

  Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, Japan

• Nakahara Tsutomu

  Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, Japan

• Ishii Kunio

  Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences, Japan

抄録

We examined the effects of Ca²⁺-channel blockers on sugar cataract formation in streptozotocin (65 mg/kg, i.v.)-induced diabetic rats that were given 5% <sc>D</sc>-glucose as drinking water. The diabetic rats were treated with an L-type Ca²⁺-channel blocker, nifedipine or verapamil, for 9 weeks from the 3rd day of streptozotocin injection. Using the full lens images of the horizontal plane captured with the new digital camera system that we developed recently, the cataract formation was quantitatively assessed in parallel with the conventional scaling method. In the animal model of diabetes mellitus, the cataracts at the peripheral region of the lens were detected 2 weeks after induction of hyperglycemia and progressed depending on the length of the diabetic period. The majority of them developed mature cataracts after 9 weeks of hyperglycemia. Nifedipine slowed the progression rate of diabetic cataracts without affecting the period of time required for the onset of this disease, whereas verapamil had no significant inhibitory effect on the diabetic cataract. These findings suggest that nifedipine may be considered as a candidate drug to suppress the progression of diabetic cataracts.<br>

収録刊行物

• Journal of Pharmacological Sciences

  Journal of Pharmacological Sciences 106 (4), 651-658, 2008

  公益社団法人 日本薬理学会

キーワード

• cataract
• diabetes
• lens
• L-type Ca²⁺ channel
• streptozotocin

詳細情報

• CRID: 1390001205181043968
• NII論文ID: 10024320181
• NII書誌ID: AA11806667
• DOI: 10.1254/jphs.fp0072294
• ISSN: 13478648
• ISSN: 13478613
• NDL書誌ID: 9469018
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I9469018
• Web Site: https://search.jamas.or.jp/link/ui/2008264710
• 本文言語コード: en
• データソース種別:
  • JaLC
  • NDL
  • Crossref
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可